Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Chondrosarcoma 1

Interventions

Filgrastim 4Cyclophosphamide 4Psychiatric Rehabilitation 3Palliative Care 3Busulfan 3aflibercept 2Vincristine 2Thalidomide 2Radiotherapy 2Paclitaxel 2Melphalan 2Leucovorin 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2Docetaxel 2Celecoxib 2Azacitidine 2Analgesia 2venetoclax 1trimetrexate glucuronate 1tazemetostat 1tanespimycin 1sargramostim 1romidepsin 1ripretinib 1pembrolizumab 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × IFL protocol × Other hematologic neoplasm × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡